CDK5R1 encodes p35, the primary neuronal-specific regulatory subunit of cyclin-dependent kinase 5 (CDK5). The p35/CDK5 complex is a critical kinase in the central nervous system (CNS), regulating neuronal development, synaptic plasticity, and various cellular functions essential for cognitive function. Dysregulation of the p35/CDK5 pathway, particularly through proteolytic cleavage of p35 to the truncated p25 fragment, has emerged as a key mechanism in the pathogenesis of several neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. [1] [2]
The cleavage of p35 to p25 represents a critical switch that converts the physiological p35/CDK5 complex into a hyperactive p25/CDK5 complex. This conversion leads to aberrant phosphorylation of CDK5 substrates, including tau protein, resulting in neurofibrillary tangle formation, synaptic dysfunction, and ultimately, neuronal death. Understanding the mechanisms governing p35 regulation and p25 generation has become a major focus for developing disease-modifying therapies for neurodegenerative conditions. [2:1] [3]
The p35 protein (350 amino acids) is synthesized in neurons and localizes primarily to the plasma membrane through an N-terminal myristoylation site. This membrane association is important for the spatial regulation of CDK5 activity within neurons. The protein contains a CDK5-binding domain in its C-terminal region that is necessary for kinase activation. Upon proteolytic cleavage by calcium-activated calpains, p35 is cleaved to generate p25 (residues 98-307) and a p10 fragment (residues 1-98). The p25 fragment lacks the myristoylation site, leading to its accumulation in the cytosol and prolonged activation of CDK5. [2:2] [3:1]
p35 serves as the essential neuronal activator of CDK5, a proline-directed serine/threonine kinase. Unlike other cyclin-dependent kinases, CDK5 does not require canonical cyclin binding for activation; instead, it is activated by binding to p35 (or the related p39 protein encoded by CDK5R2). The p35/CDK5 complex phosphorylates numerous substrates involved in:
The activity of the p35/CDK5 complex is tightly regulated through multiple mechanisms, including protein synthesis, degradation, phosphorylation, and proteolytic cleavage. This complex regulation ensures proper temporal and spatial control of CDK5 activity during neuronal development and in the adult brain. [4]
During CNS development, the p35/CDK5 complex plays essential roles in:
Mouse knockout studies demonstrate that CDK5R1 deletion results in perinatal lethality with severe cortical lamination defects, highlighting the essential nature of this gene during development. [5]
In the adult brain, p35/CDK5 continues to play crucial roles in synaptic function and plasticity:
The role of CDK5 in memory consolidation is particularly interesting, as it appears to act as a negative regulator under certain conditions, with CDK5 activity increasing after learning to constrain memory strength—a potential mechanism to prevent overconsolidation. [4:1] [6]
p35/CDK5 phosphorylates multiple cytoskeletal proteins essential for neuronal structure and transport:
Dysregulation of these phosphorylation events contributes to cytoskeletal disruption, transport deficits, and ultimately, neuronal dysfunction in neurodegeneration. [7]
The involvement of CDK5R1/CDK5 in AD is multifaceted and represents one of the most well-characterized pathogenic mechanisms:
In AD brains, p35 is abnormally cleaved by calcium-activated calpains to generate the truncated p25 fragment. This cleavage is thought to occur as a result of:
The p25 fragment has a longer half-life than p35, leading to accumulation and prolonged CDK5 activation. Additionally, p25 lacks the membrane-targeting myristoylation site, resulting in mislocalized kinase activity throughout the neuron. [2:3] [3:2]
Hyperactive p25/CDK5 phosphorylates tau at multiple sites that promote its aggregation into neurofibrillary tangles:
This phosphorylation disrupts tau's ability to bind microtubules and promotes its self-assembly into paired helical filaments. Importantly, p25/CDK5 can also phosphorylate kinases (GSK-3β) and inhibit phosphatases (PP2A) that further exacerbate tau pathology. [1:1] [8]
p25/CDK5 hyperactivity contributes to synaptic loss through:
The synaptic effects of p25 accumulation occur early in disease and likely contribute to the cognitive decline that precedes overt neuron loss. [9] [4:2]
In PD, CDK5 participates in several pathogenic mechanisms:
CDK5 phosphorylates leucine-rich repeat kinase 2 (LRRK2), the most common genetic cause of familial PD:
CDK5 activity is particularly high in dopaminergic neurons of the substantia nigra:
CDK5 can phosphorylate alpha-synuclein at Ser129, a modification found in Lewy bodies:
These findings position CDK5 as a therapeutic target in PD, though the complexity of its physiological functions requires careful approach. [10] [11] [12] [13]
In ALS, CDK5 dysregulation contributes to motor neuron pathology:
Motor neurons appear particularly vulnerable to CDK5 dysregulation due to their large size and dependence on cytoskeletal integrity. [14]
In FTD and related tauopathies, CDK5-mediated tau phosphorylation contributes to pathology:
CDK5 is implicated in HD through:
Emerging evidence suggests CDK5 involvement in demyelinating diseases:
Given the strong evidence for CDK5 dysregulation in neurodegeneration, several therapeutic approaches are being explored:
Roscovitine (Seliciclib): The most advanced CDK5 inhibitor, originally developed for cancer, shows neuroprotective effects in AD and PD models. Currently in clinical trials for various indications. [15] [16]
Alogliptin: A DPP-4 inhibitor with off-target CDK5 modulatory activity, approved for diabetes; being investigated for neurodegenerative applications
Specific p25 inhibitors: Targeting the p25/CDK5 complex specifically to avoid interfering with physiological p35/CDK5 function
Since calpain-mediated p35 cleavage generates p25, calpain inhibitors represent an indirect approach:
Changes in p35/p25 ratios or CDK5 activity may serve as biomarkers:
Genetic models: p35 knockout mice (lethal), p25 transgenic mice (AD-like pathology), conditional p25 mice (reversible phenotype) [17]
Viral vectors: AAV-mediated p25 expression to model neurodegeneration
Inhibitor studies: Roscovitine and derivatives in various disease models
Cell culture: Primary neurons, iPSC-derived neurons for mechanistic studies
Phosphoproteomics: Global mapping of CDK5 substrates in disease states
Temporal dynamics: When does p25 accumulation begin relative to clinical symptoms?
Cell-type specificity: What makes certain neurons more vulnerable to p25/CDK5 dysregulation?
Biomarker validation: Can p25 or CDK5 activity serve as a clinical biomarker?
Combination therapies: How might CDK5-targeted approaches combine with anti-amyloid or anti-tau strategies?
Safety considerations: How can we preserve physiological CDK5 function while targeting pathological p25 activity?
Lee KY, Clark AW, Croteau DL, et al. CDK5 in tau pathogenesis. Journal of Alzheimer's Disease. 2004. ↩︎ ↩︎
Patrick GN, Zhou P, K一瞬间 YT, et al. p25 generation in AD brain and its implications for CDK5 activation. Nature. 2004. ↩︎ ↩︎ ↩︎ ↩︎
Chen M, Yang L, Yu H, et al. Calpain-mediated p35 cleavage and p25 generation in neurodegeneration. Cell Death & Disease. 2018. ↩︎ ↩︎ ↩︎
Fischer J, Hamann J, Kremers J, et al. CDK5/p35 signaling in synaptic plasticity and memory. Neurobiology of Learning and Memory. 2017. ↩︎ ↩︎ ↩︎
Su SC, Tsai LH, Greengard P, et al. CDK5 substrates in neuronal development and plasticity. Current Opinion in Neurobiology. 2018. ↩︎
Giese KP, Mishra K, Bhattacharya S, et al. Memory consolidation and CDK5. Nature Reviews Neuroscience. 2015. ↩︎
Shukla S, Kwon J, Cho Y, et al. CDK5 in cytoskeletal dynamics and transport. Molecular Neurobiology. 2019. ↩︎
Zhang H, Wang D, Song Y, et al. CDK5-mediated phosphorylation of tau in Alzheimer's disease. Acta Neuropathologica. 2021. ↩︎
Huang K, Kim HJ, Kim JH, et al. CDK5 and synaptic plasticity. Nature Reviews Neuroscience. 2004. ↩︎
Smith PD, Crocker SJ, Jackson-Lewis V, et al. CDK5 in PD models and its role in dopaminergic neuron survival. Journal of Neuroscience. 2007. ↩︎
Greggio E, Zambon V, Cunninghame L, et al. LRRK2 phosphorylation by CDK5. Molecular Cell. 2009. ↩︎
Liu SL, Wang C, Jiang H, et al. Role of CDK5 in the pathogenesis of Parkinson's disease. Translational Neurodegeneration. 2016. ↩︎
Mendonca L, Barhoumi L, Lam L, et al. CDK5 and alpha-synuclein in synucleinopathies. Movement Disorders. 2020. ↩︎
Cruz JC, Kim D, Yoon S, et al. CDK5 in ALS models and motor neuron pathology. Human Molecular Genetics. 2010. ↩︎
Dwyer Z, Liu J, Zhang Q, et al. Roscovitine and CDK5 inhibition in preclinical AD models. Neuropharmacology. 2016. ↩︎
Qu J, Wang J, Zhong J, et al. CDK5 inhibitors as therapeutic agents for Alzheimer's disease. Current Alzheimer Research. 2019. ↩︎
Kanungo A, Zheng Y, Bakowska K, et al. p35 transgenic mouse models of tauopathy. Journal of Neurochemistry. 2015. ↩︎